Novel Agents and Approaches for Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel Agents and Approaches for Advanced Renal Cell Carcinoma

Published:2012-09 Issue:3 Volume:188 Page:707-715
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Figlin Robert¹,Sternberg Cora²,Wood Christopher G.³

Affiliation:

1. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California

2. Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy

3. Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference49 articles.

1. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review;Gupta;Cancer Treat Rev,2008

2. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy;Hudes;J Natl Compr Canc Netw,2011

3. EAU guidelines on renal cell carcinoma: the 2010 update;Ljungberg;Eur Urol,2010

4. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3;Hu-Lowe;Clin Cancer Res,2008

5. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma;Rini;J Clin Oncol,2009

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-Related Therapeutic Potential of Epimedium and Its Extracts;Nutrition and Cancer;2024-07-26

2. Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma;Cancers;2023-06-12

3. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy;Cancer Cell International;2022-12-12

4. A Clinical Radiomics Nomogram Was Developed by Integrating Radiomics Signatures and Clinical Variables to Distinguish High-Grade ccRCC from Type 2 pRCC;Journal of Oncology;2022-08-26

5. Comprehensive assessments of immuno‐oncology drug‐based combination therapies as first‐line treatment for advanced renal cell carcinoma;International Journal of Urology;2022-05-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3